Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38703388.
- Also identified by DOI 10.1093/cid/ciae242 and PMC identifier 11650856.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.
Medical subject headings
- HIV Infections
- Pyridones
- Rilpivirine
- Pregnancy Complications, Infectious
- Anti-HIV Agents